Last reviewed · How we verify
Anhydrous Amiloride Hydrochloride
Amiloride is a potassium-sparing diuretic that blocks sodium reabsorption in the collecting duct of the nephron, thereby increasing sodium and water excretion while retaining potassium.
Amiloride is a potassium-sparing diuretic that blocks sodium reabsorption in the collecting duct of the nephron, thereby increasing sodium and water excretion while retaining potassium. Used for Edema associated with congestive heart failure, Hypertension, Hypokalemia prevention in patients on loop or thiazide diuretics.
At a glance
| Generic name | Anhydrous Amiloride Hydrochloride |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Potassium-sparing diuretic |
| Target | Epithelial sodium channel (ENaC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amiloride acts as an epithelial sodium channel (ENaC) inhibitor in the distal tubule and collecting duct of the kidney. By blocking sodium reabsorption, it promotes natriuresis and diuresis while preventing potassium loss, making it useful in conditions requiring fluid removal without hypokalemia. It is often used in combination with loop or thiazide diuretics to counteract their potassium-wasting effects.
Approved indications
- Edema associated with congestive heart failure
- Hypertension
- Hypokalemia prevention in patients on loop or thiazide diuretics
Common side effects
- Hyperkalemia
- Headache
- Dizziness
- Nausea
- Muscle weakness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: